Entourage Health reports FY results
- Entourage Health press release (OTCQX:ETRGF): FY Adjusted EBITDA of -$14.1M decreased 51% compared to the previous year.
- Revenue of $54.54M (-1.2% Y/Y).
Entourage Health has set key priorities for 2023: With a strong commitment to delivering exceptional cannabis products, Entourage has unveiled its business outlook for the year 2023, focusing on greater shareholder return, centered around two key pillars: profitability and quality products.
Entourage is confident its product quality, offerings, and brand positioning will increase net revenue, gross profit, and adjusted EBITDA throughout 2023. With a steady cost base, this projected growth will improve operating leverage, positioning Entourage as a leading player in the industry going forward.